BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...
The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...
The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...
There have been breakthroughs in cystic fibrosis treatments over the years that have transformed outcomes for many patients, ...
The results represent a "historic" moment in cystic fibrosis care. Vertex has announced successful results from two Phase III studies of Trikafta (elexacaftor ...
The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the ...
OMAHA, Nebraska (WPVI) -- A newly-approved drug is bringing hope to many people dealing with cystic fibrosis. CF slowly robs patients of their breathing, choking lungs and other organs with thick ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey ...
Courtney Boccio wasn’t sure what to expect when she started a clinical trial for a new drug aimed at helping people with cystic fibrosis in the spring of 2018. The 25-year-old Huntington woman was ...
Vertex Pharmaceuticals Inc. VRTX announced that the FDA has accepted its supplemental new drug application (sNDA) for the label expansion of its triple combination ...